Market Place
Sourcing Support
Corvus Pharma to Present at the 43rd Annual J.P. Morgan Conference
07 Jan 2025 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Announces Data from Soquelitinib Trial
18 Dec 2024 //
GLOBENEWSWIRE
Corvus to Announce Data on Soquelitinib for Atopic Dermatitis
17 Dec 2024 //
GLOBENEWSWIRE
Corvus Pharma Publishes ITK Inhibition Data with Soquelitinib
04 Dec 2024 //
GLOBENEWSWIRE
Corvus Pharma Highlights Soquelitinib for Systemic Sclerosis
14 Nov 2024 //
GLOBENEWSWIRE
Corvus Pharma Business Update & Reports Q3 2024 Financial Results
12 Nov 2024 //
GLOBENEWSWIRE
Corvus Presents Ciforadenant Data in Prostate Cancer
09 Nov 2024 //
GLOBENEWSWIRE
Corvus Pharma to Business Update & Q3 Financial Results on Nov 12
05 Nov 2024 //
GLOBENEWSWIRE
Corvus Pharma Initiates Phase 3 Trial Of Soquelitinib For PTCL
10 Sep 2024 //
GLOBENEWSWIRE
Corvus Pharmaceuticals to Present at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Corvus Pharma Reports Q2 2024 Results And Business Update
06 Aug 2024 //
GLOBENEWSWIRE
Corvus Gets FDA Fast Track For Soquelitinib In PTCL
01 Aug 2024 //
GLOBENEWSWIRE
Corvus Pharmaceuticals To Report Q2 2024 Results On August 6
31 Jul 2024 //
GLOBENEWSWIRE
Soquelitinib Shows Promise For Inflammatory Diseases In Preclinical Data
25 Jul 2024 //
GLOBENEWSWIRE
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
30 May 2024 //
GLOBENEWSWIRE
Corvus Provides Business Update, Q1 2024 Financial Results
06 May 2024 //
GLOBENEWSWIRE
Corvus Pharma Prices $30.6M Direct Offering
02 May 2024 //
GLOBENEWSWIRE
Corvus Pharma Q1 2024 Results, Business Update On May 6
02 May 2024 //
GLOBENEWSWIRE
Corvus: Soquelitinib Phase 1 Clinical Trial for Atopic Dermatitis
09 Apr 2024 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Provides Business Update & Reports4Q FYR 2023
19 Mar 2024 //
GLOBENEWSWIRE
Corvus Pharma to Provide Fourth Quarter and Full Year 2023 Financial Results
13 Mar 2024 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data
12 Feb 2024 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib
08 Feb 2024 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
06 Feb 2024 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
23 Jan 2024 //
GLOBENEWSWIRE
Corvus Presents New Interim Soquelitinib Data from its Phase 1/1b Trial
09 Dec 2023 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data
02 Nov 2023 //
GLOBENEWSWIRE
Corvus Announces Publication of Data Showing Potential of Soquelitinib
01 Nov 2023 //
GLOBENEWSWIRE
Corvus Pharma to Report Third Quarter Financial Results on November 7, 2023
31 Oct 2023 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Confirms Planned Initiation of CPI-818 Phase 3 Trial
06 Sep 2023 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Corvus to Report Second Quarter Financial Results on August 8, 2023
01 Aug 2023 //
GLOBENEWSWIRE
Corvus Announces Publication of Preclinical Data ITK with Soquelitinib
06 Jul 2023 //
GLOBENEWSWIRE
Corvus Pharma Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR
29 Jun 2023 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Presents New CPI-818 Interim Data
15 Jun 2023 //
GLOBENEWSWIRE
Corvus touts early data on T cell lymphoma drug, makes PhIII plans
15 Jun 2023 //
ENDPTS
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Corvus Pharma to Present New CPI-818 Data at International Conference
17 May 2023 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Provides Business Update and Reports 1Q 2023 FYR
08 May 2023 //
GLOBENEWSWIRE
Corvus to Provide Business Update and Report 1Q 2023 FYR on May 8, 2023
20 Apr 2023 //
GLOBENEWSWIRE
Corvus Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition
17 Apr 2023 //
GLOBENEWSWIRE
CPI-818 Data Highlights Potential for ITK Inhibition as Immunotherapy Approach
03 Apr 2023 //
GLOBENEWSWIRE
Corvus pauses plans to start eczema trial to focus on cancer
29 Mar 2023 //
FIERCE BIOTECH
Corvus Reports Fourth Quarter and Full Year 2022 Financial Results
28 Mar 2023 //
GLOBENEWSWIRE
Corvus to Report Q4 and Full Year 2022 Financial Results on March 28, 2023
21 Mar 2023 //
GLOBENEWSWIRE
Corvus to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition
14 Mar 2023 //
GLOBENEWSWIRE
Corvus Pharma Announces New Data Demonstrating CPI-818 Potential
21 Feb 2023 //
GLOBENEWSWIRE
Corvus Presents Updated Data from CPI-818 (ITK Inhibitor) Ph 1/1b Trial at 64th
12 Dec 2022 //
GLOBENEWSWIRE
Corvus Pharma to Host Investor Conference Call and Webcast on Dec12, 2022
05 Dec 2022 //
GLOBENEWSWIRE
Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data
03 Nov 2022 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Provides Business Update and Reports 3Q FYR
03 Nov 2022 //
GLOBENEWSWIRE
Corvus to Report Third Quarter 2022 Financial Results on November 3, 2022
27 Oct 2022 //
GLOBENEWSWIRE
Corvus Pharma Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant
25 Oct 2022 //
GLOBENEWSWIRE
Corvus Pharma Announces Partner Angel Pharmaceuticals Received IND Phase 1/1b
26 Sep 2022 //
GLOBENEWSWIRE
Corvus Pharma Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Corvus Pharmaceuticals to Report Second Quarter 2022 Financial Results
28 Jul 2022 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Appoints Dr. James Rosenbaum SVPof Research
21 Jul 2022 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium
10 May 2022 //
GLOBENEWSWIRE
Corvus Pharmaceuticals Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
